Cardioprotective effects of incretin during ischaemia-reperfusion. - Wikidata - awgldk - TriplyDB

Cardioprotective effects of incretin during ischaemia-reperfusion.

Cardioprotective effects of incretin during ischaemia-reperfusion.

http://www.wikidata.org/entity/Q38002006

about

Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis.Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes.Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury.Cardiomyocyte changes in the metabolic syndrome and implications for endogeneous protective strategies.Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Pharmacology of Ischemia-Reperfusion. Translational Research Considerations.Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition.Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.Incretin hormones as immunomodulators of atherosclerosis.Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.Incretin attenuates diabetes-induced damage in rat cardiac tissue.Di-peptidyl peptidase-4 inhibitor sitagliptin protects vascular function in metabolic syndrome: possible role of epigenetic regulation.

P2860

Q36288965-833E3481-5B0B-496F-ACF5-C171960AACB9 Q36366910-E98F21E4-D6BF-415D-A791-F97FB9B6B3F0 Q36976130-F4F663DF-9178-4A3C-A405-6336ADFA9854 Q38137849-4614E887-A898-413A-B8CA-CE19B281A657 Q38191658-967AB1DC-6F74-4B27-82F3-7A17BC20BC39 Q38194363-9CA936B8-9160-4CF2-9D71-D3B50381D2B0 Q38219490-94F7F89D-EFD6-4295-B51E-64DBD7290FE5 Q38842544-51600425-F939-438E-854B-6BA421658756 Q39277184-BED5C087-7BB8-43A6-A257-850C25E77E01 Q41853657-15AF5EAE-95CB-46BA-B97E-D33FCB6A42F9 Q41882168-BC57C8B3-E195-4642-9046-3D5024D15C5C Q47288494-C9AA3130-A7BB-46D9-8ED9-486100830F39 Q53836780-06F36405-056B-47DC-A393-25EBD2AD69E2 Q54351970-0EC7A3C9-C4B0-457E-9F6F-D7C91EE07407

P2860

Cardioprotective effects of incretin during ischaemia-reperfusion.

http://www.wikidata.org/entity/Q38002006

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cardioprotective effects of incretin during ischaemia-reperfusion.

@en

type

label

Cardioprotective effects of incretin during ischaemia-reperfusion.

@en

prefLabel

Cardioprotective effects of incretin during ischaemia-reperfusion.

@en

P1433

Q38002006-1458FBD0-BA62-4F65-833A-E8E1A89A61F0

P1476

Q38002006-E8CE8704-F624-4EB3-8A80-56C6DE4A29D4

P2093

Q38002006-195061D4-85EA-4669-B886-F7063E141DBA

Q38002006-6EF442A8-7DE0-4A5A-B370-338DA759539D

Q38002006-B025214F-82B6-4BE5-ADE2-4C7DDDE4BA41

P2860

Q38002006-08016126-B7EA-4CA9-BDC2-3BFEDBAD6880

Q38002006-0BA0D7CA-32BF-4624-B42A-C44E2166C0BD

Q38002006-10E6153B-1FD1-47FF-9CB9-5E10F4FA0B66

Q38002006-1EED74A8-8179-4109-B404-B70C7C49075D

Q38002006-1FDCCEB1-D1EC-4AF7-864D-308F6A058B56

Q38002006-20CBF8A0-AF4B-4D53-8FC8-4B814C05BB6C

Q38002006-2746D4D7-D6E1-48B1-9A2D-E4A4EFA547B5

Q38002006-2C30BF74-7DBB-469E-803F-F7C5BCB80851

Q38002006-2F53F8D7-7FA5-47B8-8983-DB838348EA55

Q38002006-339CA9CB-611A-4079-8E0E-241CF0E9B8D5

P304

Q38002006-847927FA-3819-45A9-BC58-CA264CCD574C

P31

Q38002006-9F25B23B-F9EA-45AD-87BA-65A2E4436769

P356

Q38002006-53B62106-DB93-45B5-997C-A410B353017E

P407

Q38002006-2DA0245C-7A18-457C-A4A0-7F0948AAE753

P433

Q38002006-CABDB04F-282E-44A8-9321-17B5874306F8

P478

Q38002006-95019744-FD05-4197-AB75-937A0A89441D

P577

Q38002006-9191FC76-303A-406A-A4A7-6360A494F668

P698

Q38002006-E6794DC5-45FE-40E1-A93E-73B54FC577F6

P356

1479164112440816

P1433

Diabetes and Vascular Disease Research

P1476

Cardioprotective effects of incretin during ischaemia-reperfusion.

@en

P2093

Kroekkiat Chinda

http://www.w3.org/2001/XMLSchema#string

Nipon Chattipakorn

http://www.w3.org/2001/XMLSchema#string

Siriporn Chattipakorn

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans.

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency

Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury.

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

P304

256-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1479164112440816

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22496404

http://www.w3.org/2001/XMLSchema#string